Several other equities analysts have also recently weighed in on GLPG. Bank of America initiated coverage on GALAPAGOS NV/S in a report on Monday. They set a “neutral” rating and a $199.00 price target on the stock. Royal Bank of Canada lifted their price objective on GALAPAGOS NV/S from $152.00 to $158.00 and gave the stock a “sector perform” rating in a report on Friday, November 15th. ValuEngine cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. TheStreet raised GALAPAGOS NV/S from a “c” rating to a “b” rating in a report on Tuesday, October 29th. Finally, Morgan Stanley dropped their target price on GALAPAGOS NV/S to $193.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $178.44.
GLPG opened at $201.63 on Wednesday. The stock has a market capitalization of $10.90 billion, a price-to-earnings ratio of -305.50 and a beta of 1.58. The firm has a 50 day moving average price of $180.19 and a 200-day moving average price of $157.19. GALAPAGOS NV/S has a twelve month low of $85.00 and a twelve month high of $202.54. The company has a quick ratio of 8.95, a current ratio of 8.95 and a debt-to-equity ratio of 0.01.
Hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its stake in shares of GALAPAGOS NV/S by 170.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 157 shares in the last quarter. Royal Bank of Canada raised its holdings in GALAPAGOS NV/S by 206.1% in the 2nd quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 169 shares during the period. Ladenburg Thalmann Financial Services Inc. bought a new position in GALAPAGOS NV/S in the 2nd quarter worth $59,000. Quantamental Technologies LLC purchased a new position in GALAPAGOS NV/S during the second quarter valued at $74,000. Finally, FNY Investment Advisers LLC purchased a new position in GALAPAGOS NV/S during the third quarter valued at $109,000. 15.28% of the stock is owned by hedge funds and other institutional investors.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Read More: What is the CAC 40 Index
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.